Mumbai, 16th December 2019: Cipla Ltd. (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as“Cipla”) has acquired the brand name and trademark rights for Vysov ® & Vysov M® (Vildagliptin+ Metformin) of the anti-diabetic drug, Vildagliptin for the Indian market.
The company has been co-marketing Vildagliptin in agreement with Novartis under brand namesVysov® & Vysov M® and has witnessed a strong uptake for the product in India for the last couple of years. It is currently available across the country.
Vildagliptin is an orally active, potent and selective DPP-4 inhibitor that improves glycemic control in patients primarily by enhancing pancreatic (α and β) islet functions. The drug is backed by strong clinical data & is therefore a widely prescribed antidiabetic medicine for adults with type 2 diabetes mellitus. The current market size of Vildagliptin is INR 818 Cr. as per IQVIA MAT Nov’ 2019 in India.
Mr. Nikhil Chopra, Executive Vice-President & Head India Business, Cipla Ltd. said “Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla’s acquisition of the trademark rights of Vysov® will enable us to contribute to easier accessof the drug in India.”